Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
72 hedge funds and large institutions have $278M invested in Dova Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 17 closing their positions.
113% more capital invested
Capital invested by funds: $131M → $278M (+$147M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
9% more funds holding
Funds holding: 66 → 72 (+6)
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
22% less call options, than puts
Call options by funds: $5.66M | Put options by funds: $7.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$23M |
| 2 |
Goldman Sachs
New York
|
+$3.85M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$3.24M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$2.72M |
| 5 |
PA
Perceptive Advisors
New York
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$7.36M |
| 3 |
Morgan Stanley
New York
|
-$5.2M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.91M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.88M |
DOVA Hedge Fund Activity: Q3 2019 in Review
72 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q3 2019, worth a combined $278M — up 113% from $131M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new DOVA positions and 17 closed out — a net gain of 6 holders — while 19 added to existing stakes and 21 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $23M. The largest seller was Fidelity Investments, cutting an estimated $13.1M.
- 72 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q3 2019, up from 66 in Q2 2019.
- Funds reported $278M of Dova Pharmaceuticals, Inc. Common Stock stock for Q3 2019, up 113% quarter-over-quarter.
- 23 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 17 closed out, a net change of +6 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Alpine Associates Management, an estimated $23M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was Fidelity Investments, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2019.